The programme was supported by an unrestricted educational grant from Abbott to the University Medical Center Schleswig-Holstein, Campus Kiel, Germany. The sponsor did not have any influence on the programme at any time.
Conflict of interest
All members of the steering committee have received reimbursement for travel, participation, and preparatory work from the University Medical Center Schleswig-Holstein, Campus Kiel.
All participants have received reimbursement for travel expenses and participation in the Hamburg consensus meeting from the University Medical Center Schleswig-Holstein, Campus Kiel.
Knud Kragballe apart from the statement mentioned above has no competing interest to declare.
Petr Arenberger, Matilda Bylaite, Nikhil Yawalkar, Thomas Rosenbach, Lars Iversen, Paolo Gisondi, Flora Balieva, Christina Antoniou, Tapio Rantanen, Adam Reich, Beatrix Volc-Platzer, and Toomas Talme apart from the statement above have no competing interest to declare.
Ulrich Mrowietz was board member or consultant or received payment for development of educational presentations including service on speakers’ bureaus or received grants/grants pending or honoraria or travel/accommodations expenses covered or reimbursed for/from Abbot, Biogen-Idec, Centocor, Essex/Schering-Plough, Janssen-Cilag, Leo Pharma, Merck, Novartis, Pfizer, Wyeth.
Phyllis Spuls got unrestricted grants for research, received payment for development of educational presentations including service on speakers’ bureaus from pharmaceutical industries that might have an interest related to the submitted work and her institution and herself is involved as principal investigator in many clinical trials financed by the pharmaceutical industries that might have an interest related to the submitted work.
Kristian Reich was board member or consultant or received payment for development of educational presentations including service on speakers’ bureaus or received travel/accommodations expenses covered or reimbursed for/from Abbot, Biogen-Idec, Centocor, Essex, Janssen-Cilag, Leo, Merck, Novartis, Pfizer, Wyeth.
Christopher E. M. Griffiths got unrestricted grants for research, received payment for development of educational presentations including service on speakers’ bureaus from pharmaceutical industries that might have an interest related to the submitted work and her institution and herself is involved as principal investigator in many clinical trials financed by the pharmaceutical industries that might have an interest related to the submitted work.
Julia Franke received travel/accommodations expenses covered or reimbursed from pharmaceutical industries that might have an interest related to the submitted work.
Alexander Nast received payment for development of educational presentations including service on speakers’ bureaus from Wyeth and Intendis.
Osvaldo Correia received payment for development of educational presentations including service on speakers’ bureaus and travel/accommodations expenses covered or reimbursed from Wyeth/Pfizer.
Esteban Dauden was board member or consultant or received grants/grants pending or payment for development of educational presentations including service on speakers’ bureaus, or travel/accommodations expenses covered or reimbursed for/from Abbott, Janssen-Cilag, Leo Pharma, Merck, Pfizer, Astellas, Schering, Wyeth.
Lajos Kémeny was board member or consultant or received grants/grants pending or received honoraria or travel/accommodations expenses covered or reimbursed for/from Abbott, Astellas, Barrier, Galderma, Leo Pharma, Novartis, Pfizer, ScheringPlough, Stiefel, UCB, Procter&Gamble, LaRoche Posay and Wyeth.
Morad Lahfa was board member or consultant or received payment for manuscript preparation or payment for development of educational presentations including service on speakers’ bureaus or travel/accommodations expenses covered or reimbursed for/from Merck Serono, Abbott, Schering-Plough, Wyeth, Leo, Galderma, Novartis, Astellas.
Tamar Nijsten was consultant for or received grants/grants pending from Abbott, Wyeth, Schering-Plough, Leo Pharma, Merck-Serono.
Siegfried Segaert got unrestricted grants for research, received payment for development of educational presentations including service on speakers’ bureaus from pharmaceutical industries that might have an interest related to the submitted work and her institution and herself is involved as principal investigator in many clinical trials financed by the pharmaceutical industries that might have an interest related to the submitted work.
Catherine Smith received grants/grants pending or payment for development of educational presentations including service on speakers’ bureaus or travel/accommodations expenses covered or reimbursed or honoraria from Abbott, Janssen-Cilag, Serono, Schering Plough and Wyeth.